Literature DB >> 25059393

Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.

Michel J Grothe1, Christina Schuster, Florian Bauer, Helmut Heinsen, Johannes Prudlo, Stefan J Teipel.   

Abstract

Similar to Alzheimer's disease (AD), dementia with Lewy bodies (DLB) is characterized by a profound degeneration of cortically-projecting cholinergic neurons of the basal forebrain (BF) and associated depletion of cortical cholinergic activity. We aimed to investigate subregional atrophy of the BF in DLB in vivo and compare it to the pattern of BF atrophy in AD. Structural MRI scans of 11 patients with DLB, 11 patients with Alzheimer's disease, and 22 healthy controls were analysed using a recently developed technique for automated BF morphometry based on high-dimensional image warping and cytoarchitectonic maps of BF cholinergic nuclei. For comparison, hippocampus volume was assessed within the same morphometric framework using recently published consensus criteria for the definition of hippocampus outlines on MRI. The DLB group demonstrated pronounced and subregion-specific atrophy of the BF which was comparable to BF atrophy in AD: volume of the nucleus basalis Meynert was significantly reduced by 20-25%, whereas rostral BF nuclei were only marginally affected. By contrast, hippocampus volume was markedly less affected in DLB compared to AD. Global cognition as determined by MMSE score was associated with BF volume in AD, but not in DLB, whereas visuoperceptual function as determined by the trail making test was associated with BF volume in DLB, but not in AD. DLB may be characterized by a more selective degeneration of the cholinergic BF compared to AD, which may be related to the differential cognitive profiles in both conditions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25059393     DOI: 10.1007/s00415-014-7439-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  76 in total

1.  Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease.

Authors:  Stefan Teipel; Helmut Heinsen; Edson Amaro; Lea T Grinberg; Bernd Krause; Michel Grothe
Journal:  Neurobiol Aging       Date:  2013-10-28       Impact factor: 4.673

2.  The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia.

Authors:  Kate de Medeiros; P Robert; S Gauthier; F Stella; A Politis; J Leoutsakos; F Taragano; J Kremer; A Brugnolo; A P Porsteinsson; Y E Geda; H Brodaty; G Gazdag; J Cummings; C Lyketsos
Journal:  Int Psychogeriatr       Date:  2010-07-01       Impact factor: 3.878

3.  Lewy bodies and response to tacrine in Alzheimer's disease.

Authors:  R Levy; S Eagger; M Griffiths; E Perry; M Honavar; A Dean; P Lantos
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

4.  Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis.

Authors:  P J Whitehouse; D L Price; A W Clark; J T Coyle; M R DeLong
Journal:  Ann Neurol       Date:  1981-08       Impact factor: 10.422

Review 5.  Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function.

Authors:  Martin Sarter; Roger L Albin; Aaron Kucinski; Cindy Lustig
Journal:  Exp Neurol       Date:  2014-05-05       Impact factor: 5.330

6.  Brain atrophy in primary progressive aphasia involves the cholinergic basal forebrain and Ayala's nucleus.

Authors:  Stefan J Teipel; Wilhelm Flatz; Nibal Ackl; Michel Grothe; Ingo Kilimann; Arun L W Bokde; Lea Grinberg; Edson Amaro; Vanja Kljajevic; Eduardo Alho; Christina Knels; Anne Ebert; Helmut Heinsen; Adrian Danek
Journal:  Psychiatry Res       Date:  2013-12-06       Impact factor: 3.222

7.  Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies.

Authors:  Nicole Chow; Dag Aarsland; Hedieh Honarpisheh; Mona K Beyer; Johanne H Somme; David Elashoff; Arvid Rongve; Ole B Tysnes; Paul M Thompson; Liana G Apostolova
Journal:  Dement Geriatr Cogn Disord       Date:  2012-08-20       Impact factor: 2.959

8.  Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease.

Authors:  Pietro Tiraboschi; Larry A Hansen; Michael Alford; Annette Merdes; Eliezer Masliah; Leon J Thal; Jody Corey-Bloom
Journal:  Arch Gen Psychiatry       Date:  2002-10

9.  Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.

Authors:  Jeffrey Cummings; Murat Emre; Dag Aarsland; Sibel Tekin; Nalina Dronamraju; Roger Lane
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

10.  The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study.

Authors:  J Janzen; D van 't Ent; A W Lemstra; H W Berendse; F Barkhof; E M J Foncke
Journal:  J Neurol       Date:  2011-06-30       Impact factor: 4.849

View more
  38 in total

1.  Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment.

Authors:  Michel J Grothe; Helmut Heinsen; Edson Amaro; Lea T Grinberg; Stefan J Teipel
Journal:  Cereb Cortex       Date:  2015-04-02       Impact factor: 5.357

Review 2.  A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.

Authors:  Jacob S Buckley; Shelley R Salpeter
Journal:  Drugs Aging       Date:  2015-06       Impact factor: 3.923

3.  The cholinergic basal forebrain in Lewy body dementia and Alzheimer's disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2014-12-12       Impact factor: 4.849

4.  Multimodal Encoding of Novelty, Reward, and Learning in the Primate Nucleus Basalis of Meynert.

Authors:  Clarissa Martinez-Rubio; Angelique C Paulk; Eric J McDonald; Alik S Widge; Emad N Eskandar
Journal:  J Neurosci       Date:  2018-01-18       Impact factor: 6.167

5.  Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer's Disease Studies.

Authors:  Liana M de Medeiros; Marco A De Bastiani; Eduardo P Rico; Patrícia Schonhofen; Bianca Pfaffenseller; Bianca Wollenhaupt-Aguiar; Lucas Grun; Florência Barbé-Tuana; Eduardo R Zimmer; Mauro A A Castro; Richard B Parsons; Fábio Klamt
Journal:  Mol Neurobiol       Date:  2019-04-29       Impact factor: 5.590

Review 6.  Effects of Prolonged Seizures on Basal Forebrain Cholinergic Neurons: Evidence and Potential Clinical Relevance.

Authors:  Filippo Sean Giorgi; Alessandro Galgani; Anderson Gaglione; Rosangela Ferese; Francesco Fornai
Journal:  Neurotox Res       Date:  2020-04-21       Impact factor: 3.911

Review 7.  Cholinergic modulation of the hippocampal region and memory function.

Authors:  Juhee Haam; Jerrel L Yakel
Journal:  J Neurochem       Date:  2017-08       Impact factor: 5.372

8.  Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies.

Authors:  Lidia Tagliafierro; Omolara-Chinue Glenn; Madison E Zamora; Thomas G Beach; Randy L Woltjer; Michael W Lutz; Ornit Chiba-Falek
Journal:  Alzheimers Dement       Date:  2017-04-18       Impact factor: 21.566

9.  Removal of p75 Neurotrophin Receptor Expression from Cholinergic Basal Forebrain Neurons Reduces Amyloid-β Plaque Deposition and Cognitive Impairment in Aged APP/PS1 Mice.

Authors:  Lei Qian; Michael R Milne; Stephanie Shepheard; Mary-Louise Rogers; Rodrigo Medeiros; Elizabeth J Coulson
Journal:  Mol Neurobiol       Date:  2018-10-29       Impact factor: 5.590

Review 10.  Neuroimaging in aging and neurologic diseases.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Handb Clin Neurol       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.